Matthew Steidle

Matthew Steidle

Auto-generated profile, based on publicly available information

Matthew Steidle

Department of Urology, University of Rochester Medical Center, Rochester, NY

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MSMatthew Steidle
Matthew Steidle
KMKamil Malshy
Kamil Malshy
THTrevor C. Hunt
Trevor C. Hunt
ZCZijing Cheng
Zijing Cheng
ALAshley Li
Ashley Li
JBJathin Bandari
Jathin Bandari

1 May 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
KMKamil Malshy
Kamil Malshy
MSMatthew Steidle
Matthew Steidle
THTrevor C. Hunt
Trevor C. Hunt
ZCZijing Cheng
Zijing Cheng
ALAshley Li
Ashley Li
JBJathin Bandari
Jathin Bandari
PURPOSE: Collaboration among trial sponsors can pool expertise and resources, potentially accelerating drug development and regulatory success. This study assessed whether collaborations between drug sponsors influence the likelihood and timing of US Food and Drug Administration (FDA) approval for phase III clinical trials in genitourinary cancers. METHODS: We queried ClinicalTrials.gov for all industry-sponsored, interventional phase III trials in genitourinary malignancies completed between January 1, 2010, and October 1, 2024. Trials involving supportive agents, nontherapeutics, or bioequivalence studies were excluded. Eligible trials were grouped by sponsorship structure: single-sponsor (SS) or sponsor-collaborator (S-C). Time to FDA approval was compared using Kaplan-Meier estimates and log-rank tests. Stratified Cox regression assessed the impact of collaboration across subgroups (disease site, stage, and previous drug approval). An additional analysis examined trials that met their primary end points. RESULTS: Seventy-eight trials met inclusion criteria from an initial 183. Of these, 51 (65.4%) were SS trials and 27 (34.6%) were S-C. FDA approval was granted for 20 of 27 S-C trials (74.1%) versus 20 of 51 SS trials (39.2%). S-C trials had significantly faster approval (hazard ratio [HR], 2.75 [95% CI, 1.46 to 5.18]; P = .0009). One- and 2-year approval rates were, respectively, 50.0% and 73.6% for S-C, compared with 19.6% and 31.4% for SS trials. Subgroup analyses confirmed consistent benefits across metastatic disease, prostate cancer, and previously approved drugs. Among the 50 trials that met their primary end points, S-C trials had a higher approval likelihood (HR, 2.23 [95% CI, 1.13 to 4.38]; P = .013). CONCLUSION: Sponsor collaboration significantly improves FDA approval rates and timelines in phase III genitourinary cancer trials, including those meeting primary end points. This strategy may enhance trial success and accelerate access to new therapies.

1 February 2026 in JU Open Plus
Verified
Journal Article
Open access
ALAshley Li
Ashley Li
KMKamil Malshy
Kamil Malshy
MSMatthew Steidle
Matthew Steidle
ZCZijing Cheng
Zijing Cheng
YJYusheng Jia
Yusheng Jia
JBJathin Bandari
Jathin Bandari
Background: Recent studies have shown growth in the number of female residents and fellows in urology, a field that has historically been male dominated. Yet, the impact on subspecialty fellowships has not been well described. Objective: To analyze trends in female representation across American Urological Association (AUA) fellowship subspecialties. Methods: Fellowship match data (2014-2025) for Society of Urological Oncology (SUO), Endourological Society (EUS), American Society of Andrology (ASA), Society of Genitourinary Reconstructive Surgeons (GURS), and Society of Pediatric Urology (SPU) were analyzed. The primary analysis assessed trends in female-matched fellowship slots. Secondary analyses examined trends in female applicants, their proportion among matched applicants, and their distribution across all matched slots. Spearman correlation (ρ) measured monotonic trends. Results: Of the 2531 applicants, 437 (17.2%) were female, increasing from 13 in 2014 to 53 in 2024 (ρ = 0.92; P < .001). Overall, 358 (81.9%) women matched, with a significant rise from 9 in 2014 to 49 in 2024 (ρ = 0.84; P = .001). This increase was driven by SUO (ρ = 0.78; P = .003), EUS (ρ = 0.76; P = .004), and GURS (ρ = 0.67; P = .017), while SPU showed a nonsignificant decline (ρ = −0.58; P = .061). The proportion of women among matched applicants rose from 11.4% in 2014 to 30.6% in 2024, with SUO showing a significant increase (ρ = 0.73; P = .007). Within the matched female cohort, SPU proportions declined sharply from 52.2% in 2016 to 18.4% in 2024 (ρ = −0.9; P < .001). Conclusion: Female-matched fellowship slots significantly increased, driven by EUS, SUO, and GURS. SPU demonstrated a decline, whereas ASA showed no significant changes.

9 April 2026 in Urology Practice
Verified
Journal Article
Closed access
THTrevor C. Hunt
Trevor C. Hunt
MSMatthew Steidle
Matthew Steidle
JBJathin Bandari
Jathin Bandari

26 May 2026 in The Prostate
Verified
Journal Article
Closed access
MSMatthew T. Steidle
Matthew T. Steidle
KMKamil Malshy
Kamil Malshy
ZCZijing Cheng
Zijing Cheng
DZDenzel Zhu
Denzel Zhu
THTrevor C. Hunt
Trevor C. Hunt
JJJean V. Joseph
Jean V. Joseph